CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.03 Billion CNY | -4.55% |
| 2022 | 4.22 Billion CNY | 26.97% |
| 2021 | 3.32 Billion CNY | 391.17% |
| 2020 | 677.21 Million CNY | 115.69% |
| 2019 | 313.98 Million CNY | 6.96% |
| 2018 | 293.55 Million CNY | 13.33% |
| 2017 | 259.03 Million CNY | 131.9% |
| 2016 | 111.7 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.46 Billion CNY | -14.12% |
| 2024 Q2 | 3.07 Billion CNY | -11.18% |
| 2023 Q2 | 3.92 Billion CNY | -5.06% |
| 2023 FY | 4.03 Billion CNY | -4.55% |
| 2023 Q4 | 4.03 Billion CNY | 5.74% |
| 2023 Q3 | 3.81 Billion CNY | -2.94% |
| 2023 Q1 | 4.13 Billion CNY | -2.04% |
| 2022 Q2 | 3.73 Billion CNY | 11.28% |
| 2022 FY | 4.22 Billion CNY | 26.97% |
| 2022 Q4 | 4.22 Billion CNY | 11.6% |
| 2022 Q3 | 3.78 Billion CNY | 1.39% |
| 2022 Q1 | 3.35 Billion CNY | 0.83% |
| 2021 Q4 | 3.32 Billion CNY | -4.0% |
| 2021 Q1 | 1.4 Billion CNY | 108.01% |
| 2021 Q2 | 3.23 Billion CNY | 129.66% |
| 2021 Q3 | 3.46 Billion CNY | 7.11% |
| 2021 FY | 3.32 Billion CNY | 391.17% |
| 2020 Q4 | 677.21 Million CNY | 80.74% |
| 2020 FY | 677.21 Million CNY | 115.69% |
| 2020 Q2 | 333.54 Million CNY | 17.35% |
| 2020 Q3 | 374.69 Million CNY | 12.34% |
| 2020 Q1 | 284.22 Million CNY | -9.48% |
| 2019 Q4 | 313.98 Million CNY | 0.0% |
| 2019 FY | 313.98 Million CNY | 6.96% |
| 2019 Q2 | 289.08 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 FY | 293.55 Million CNY | 13.33% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q3 | 293.55 Million CNY | 0.0% |
| 2018 Q4 | 293.55 Million CNY | 0.0% |
| 2017 FY | 259.03 Million CNY | 131.9% |
| 2016 FY | 111.7 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -2733.355% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 44.355% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -2265.721% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -468.073% |
| Qianhai Health Holdings Limited | 94 Million HKD | -4188.538% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | -333.447% |
| Essex Bio-Technology Limited | 903.78 Million HKD | -346.054% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -505.864% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -484.55% |
| SSY Group Limited | 4.49 Billion HKD | 10.293% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -999.201% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | -269.681% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 97.607% |